摘要
目的:分析血清白细胞介素-6(IL-6)、微小RNA-17-5p(miR-17-5p)水平与卵巢癌患者化疗后生存期的相关性。方法:选取行手术治疗联合术后化疗的65例卵巢癌患者作为病例组,选取50名健康体检者作为对照组,选取50例良性卵巢疾病患者作为良性疾病组,对病例组患者术前及术后14d的血清IL-6、miR-17-5p水平进行检测和比较,对良性疾病组和对照组研究对象的血清IL-6、miR-17-5p水平进行检测和比较,对病例组患者进行随访,对其总生存期(OS)和无疾病进展生存期(PFS)进行观察和比较。结果:病例组患者血清IL-6、miR-17-5p表达水平显著高于良性疾病组,良性疾病组患者的血清IL-6、miR-17-5p表达水平显著高于对照组,各组之间的差异均有统计学意义(P<0.05)。病例组患者术后14d血清IL-6、miR-17-5p表达水平较手术前显著下降,差异均有统计学意义(P<0.05)。血清IL-6、miR-17-5p高表达的卵巢癌患者中TNM分期为Ⅲ~Ⅳ期的比例较高,差异均有统计学意义(P<0.05)。血清IL-6、miR-17-5p高表达卵巢癌患者的OS和PFS明显短于血清IL-6、miR-17-5p低表达患者,差异均有统计学意义(P<0.05)。血清IL-6和miR-17-5p同时呈现低表达的卵巢癌患者的OS和PFS水平最高,血清IL-6或miR-17-5p其中之一呈现高表达卵巢癌患者的OS和PFS水平居中,而血清IL-6和miR-17-5p同时呈现高表达的OS和PFS水平最低,差异均有统计学意义(P<0.05)。结论:卵巢癌患者可表现为血清IL-6、miR-17-5p水平的显著升高,在手术治疗后,其水平会出现下降,术前较高的血清IL-6、miR-17-5p表达水平与较短的生存期和不良预后具有关联性,可作为预测患者预后的辅助指标。
Objective： To analyze the correlation between the serum interleukin-6 （IL-6） and microRNA-17-5p （miR-17-5p） levels and the survivals after chemotherapy of the patients with ovarian cancer. Methods： 65 patients with ovarian cancer treated with surgery combined with postoperative chemotherapy were selected as the case group. 50 healthy subjects were selected as the control groups. 50 patients with benign ovarian diseases were selected as the benign disease group. The serum levels of IL-6 and miR-17-5p before the surgery and at 14 d after the surgery of the patients in the case group were detected and compared. The serum levels of IL-6 and miR-17-5p of the subjects in the control group and the benign disease group were detected and compared. The patients in the case group were followed up, the overall survival period （OS） and the progression free survival （PFS） were observed and compared. Results： The serum levels oflL-6 and miR-17-5p of the patients in the case group were significantly higher than those in the benign disease group. The serum levels oflL-6 and miR-17-5p of the patients in the benign disease were significantly higher than those in the control group, there were significant differences between the groups （P〈0.05）. The serum levels oflL-6 and miR-17-5p of the patients in the case group at 14d after the surgery decreased significantly compared with those before the operation, the differences were statistically significant （P〈0.05）. The ratio in TNM III - IV stages in the patients with high expression of serum IL-6 or miR-17-5p was higher than that with low expression of serum IL-6 or miR-17-5p, the differences were statistically significant （P〈0.05）. OS and PFS of the patients with high expression of serum IL-6 or miR-17-5p were significantly shorter than those with low expression of serum IL-6 or miR-17-5p, the differences were statistically significant （P〈0.05）. OS and PFS of the patients with low expressions of both serum IL-6 and miR-17-5p were the longest, followed by the patients with low expression of single serum IL-6 or miR-17-5p, and OS and PFS of the patients with high expressions of both serum IL-6 and miR-17-5p were the shortest, the differences were statistically significant （P〈0.05）. Conclusions： The patients with ovarian cancer show the significant increases of serum IL-6, miR-17-5p levels and the levels decline after the surgery. The high expressions of preoperative serum IL-6, miR-17-5p are associated with shorter survivals and poor prognosis, can be used as an indicator to predict patients prognosis.
出处
《现代生物医学进展》
CAS
2017年第28期5540-5547,共8页
Progress in Modern Biomedicine
基金
陕西省科学技术厅基金项目(2015SF131)
